1
|
Topcu A, Yasin AI, Besiroglu M, Sucuoglu Isleyen Z, Alaca Topcu Z, Simsek M, Turk HM, Seker M, Soysal P. Prevalence and co-incidence of geriatric syndromes according to the ECOG performance status in older cancer patients. Front Med (Lausanne) 2024; 11:1331246. [PMID: 38439897 PMCID: PMC10910106 DOI: 10.3389/fmed.2024.1331246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Accepted: 01/29/2024] [Indexed: 03/06/2024] Open
Abstract
Background Geriatric syndromes may be more common in older cancer patients than in those without cancer. Geriatric syndromes can cause poor clinical outcomes. The Eastern Cooperative Oncology Group Performance Status (ECOG-PS) is often used as a clinically reported functional status score in oncology practice. Methods Our study was designed as a cross-sectional study and included 218 older cancer patients. This study aimed to determine the prevalence and relationship of geriatric syndromes according to the ECOG-PS in older cancer patients. Results The mean age of 218 participants was 73.0 ± 5.6 years, with 47.7% being women and 52.3% men in our study. ECOG-PS 0, 1, and 2 groups contained 51, 39, and 10% of the patients, respectively. The mean number of geriatric syndromes in the ECOG 0, 1, and 2 groups was 2.3 ± 2.2, 4.3 ± 2.4, and 5.7 ± 2.1, respectively (p < 0.001). After adjusting for age and sex, it was determined that dynapenia was 2.9 times, probable sarcopenia was 3.5 times, frailty was 4.2 times, depression was 2.6 times, malnutrition was 3.3 times, insomnia 2 was.2 times, falls was 2.5 times, and the risk of falling (TUG) was 2.4 times more likely in those with ECOG-PS 1 compared to those with ECOG-PS 0. In addition, it was found that dynapenia was 6 times, probable sarcopenia was 6.8 times, frailty was 10.8 times, depression was 3.3 times, malnutrition was 6.3 times, the risk of falling (Tinnetti Balance) was 28 times, and the risk of falling (TUG) was 13.6 times more likely in those with ECOG-PS 2 compared to those with ECOG-PS 0. Conclusion Our study found that the prevalence of geriatric syndromes increased as the ECOG-PS increased. Geriatric syndromes and their co-incidence were common in older cancer patients, even in normal performance status. Oncologists should incorporate geriatric syndromes into the decision-making process of cancer treatment to maximize the impact on clinical outcomes in older patients with cancer.
Collapse
Affiliation(s)
- Atakan Topcu
- Bezmialem Vakif University Hospital, İstanbul, Türkiye
| | | | - Mehmet Besiroglu
- Istanbul Medeniyet University Göztepe Prof Dr Süleyman Yalçın City Hospital, İstanbul, Türkiye
| | | | - Zeynep Alaca Topcu
- Istanbul Medeniyet University Göztepe Prof Dr Süleyman Yalçın City Hospital, İstanbul, Türkiye
| | - Melih Simsek
- Bezmialem Vakif University Hospital, İstanbul, Türkiye
| | | | - Mesut Seker
- Bezmialem Vakif University Hospital, İstanbul, Türkiye
| | - Pinar Soysal
- Bezmialem Vakif University Hospital, İstanbul, Türkiye
| |
Collapse
|
2
|
Simsek M, Besiroglu M, Akcakaya A, Topcu A, Yasin AI, Isleyen ZS, Seker M, Turk HM. Local interventions for colorectal cancer metastases to liver and lung. Ir J Med Sci 2023; 192:2635-2641. [PMID: 36929352 DOI: 10.1007/s11845-023-03340-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2023] [Accepted: 03/06/2023] [Indexed: 03/18/2023]
Abstract
BACKGROUND Colorectal cancer is a common cause of cancer-related deaths. About 1/3 of all cases present with distant metastasis, with the liver as the leading site and the lung as the most common extra-abdominal site. AIMS It was aimed to evaluate the clinical characteristics and the outcomes of colorectal cancer patients with liver or lung metastasis who had received local treatments. METHODS This is a retrospective, cross-sectional, and descriptive study. The study was performed with colorectal cancer patients that referred to the medical oncology clinic of a university hospital between December 2013 and August 2021. RESULTS A total number of 122 patients who have received local treatments were included. Radiofrequency ablation was applied in 32 patients (26.2%), metastasis was surgically resected in 84 patients (68.9%), and stereotactic body radiotherapy was preferred in six patients (4.9%). At the first follow-up control after completion of local or multimodal treatment, no residual tumor was determined with radiological assessment in 88 patients (72.1%). The median progression-free survival (16.7 months vs 9.7 months) (p = .000) and the median overall survival (37.3 months vs 25.5 months) (p = .004) of these patients were significantly better than the patients with residual disease. CONCLUSIONS Local interventions that are applied to highly selected patients may improve the survival of metastatic colorectal cancer patients. A close follow-up after local therapies is important to diagnose recurrent disease because repeated local interventions may be possible to achieve better outcomes.
Collapse
Affiliation(s)
- Melih Simsek
- Department of Internal Medicine, Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey.
| | - Mehmet Besiroglu
- Department of Internal Medicine, Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| | - Adem Akcakaya
- Department of General Surgery, Bezmialem Vakif University, Istanbul, Turkey
| | - Atakan Topcu
- Department of Internal Medicine, Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| | - Ayse Irem Yasin
- Department of Internal Medicine, Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| | - Zehra Sucuoglu Isleyen
- Department of Internal Medicine, Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| | - Mesut Seker
- Department of Internal Medicine, Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| | - Haci Mehmet Turk
- Department of Internal Medicine, Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| |
Collapse
|
3
|
Gultekin MA, Peker AA, Oktay AB, Turk HM, Cesme DH, Shbair ATM, Yilmaz TF, Kaya A, Yasin AI, Seker M, Mayadagli A, Alkan A. Differentiation of lung and breast cancer brain metastases: Comparison of texture analysis and deep convolutional neural networks. J Clin Ultrasound 2023; 51:1579-1586. [PMID: 37688435 DOI: 10.1002/jcu.23558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/30/2023] [Revised: 08/29/2023] [Accepted: 08/30/2023] [Indexed: 09/10/2023]
Abstract
PURPOSE Metastases are the most common neoplasm in the adult brain. In order to initiate the treatment, an extensive diagnostic workup is usually required. Radiomics is a discipline aimed at transforming visual data in radiological images into reliable diagnostic information. We aimed to examine the capability of deep learning methods to classify the origin of metastatic lesions in brain MRIs and compare the deep Convolutional Neural Network (CNN) methods with image texture based features. METHODS One hundred forty three patients with 157 metastatic brain tumors were included in the study. The statistical and texture based image features were extracted from metastatic tumors after manual segmentation process. Three powerful pre-trained CNN architectures and the texture-based features on both 2D and 3D tumor images were used to differentiate lung and breast metastases. Ten-fold cross-validation was used for evaluation. Accuracy, precision, recall, and area under curve (AUC) metrics were calculated to analyze the diagnostic performance. RESULTS The texture-based image features on 3D volumes achieved better discrimination results than 2D image features. The overall performance of CNN architectures with 3D inputs was higher than the texture-based features. Xception architecture, with 3D volumes as input, yielded the highest accuracy (0.85) while the AUC value was 0.84. The AUC values of VGG19 and the InceptionV3 architectures were 0.82 and 0.81, respectively. CONCLUSION CNNs achieved superior diagnostic performance in differentiating brain metastases from lung and breast malignancies than texture-based image features. Differentiation using 3D volumes as input exhibited a higher success rate than 2D sagittal images.
Collapse
Affiliation(s)
- Mehmet Ali Gultekin
- Department of Radiology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey
| | - Abdusselim Adil Peker
- Department of Radiology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey
| | - Ayse Betul Oktay
- Department of Computer Engineering, Yildiz Technical University, Istanbul, Turkey
| | - Haci Mehmet Turk
- Department of Medical Oncology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey
| | - Dilek Hacer Cesme
- Department of Radiology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey
| | - Abdallah T M Shbair
- Department of Medical Oncology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey
| | - Temel Fatih Yilmaz
- Department of Radiology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey
| | - Ahmet Kaya
- Department of Radiology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey
| | - Ayse Irem Yasin
- Department of Medical Oncology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey
| | - Mesut Seker
- Department of Medical Oncology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey
| | - Alpaslan Mayadagli
- Department of Radiation Oncology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey
| | - Alpay Alkan
- Department of Radiology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey
| |
Collapse
|
4
|
Sucuoglu Isleyen Z, Besiroglu M, Yasin AI, Simsek M, Topcu A, Smith L, Akagunduz B, Turk HM, Soysal P. The risk of malnutrition and its clinical implications in older patients with cancer. Aging Clin Exp Res 2023; 35:2675-2683. [PMID: 37644257 DOI: 10.1007/s40520-023-02538-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Accepted: 08/17/2023] [Indexed: 08/31/2023]
Abstract
AIM Malnutrition is a common geriatric syndrome with multiple negative outcomes including mortality. However, there is a scarcity of literature that focuses on the relationship between malnutrition risk and its clinical implications on geriatric syndromes and mortality among cancer patients. The aim of this study is to determine the clinical importance of malnutrition risk in geriatric oncology practice. METHOD 180 patients with cancer who were ≥ 65 years were included in the study. All patients were questioned in terms of geriatric syndromes, including polypharmacy, frailty, probable sarcopenia, fall risk, dynapenia, depression, cognitive impairment, insomnia, and excessive daytime sleepiness. Mini Nutritional Assessment scores > 23.5 and 17-23.5 were categorized as well-nourished and malnutrition risk, respectively. RESULTS Of the 180 patients (mean age 73.0 ± 5.6 years, female: 50%), the prevalence of malnutrition risk was 28.9%. There was no statistically significant difference between the groups in terms of age, gender, education, marital status, body mass index, and comorbidities except for chronic obstructive pulmonary disease (p > 0.05). After adjustment for age, sex, and body mass index; polypharmacy (odds ratio [OR]: 3.17; 95% confidence interval [CI], 1.48-6.81), reduced calf circumference (OR: 3.72; 95% CI, 1.22-11.38), fall risk (OR: 2.72; 95% CI, 1.03-7.23), depression (OR: 6.24; 95% CI, 2.75-14.18), insomnia (OR: 4.89; 95% CI, 2.16-11.05), and frailty (OR: 2.44; 95% CI, 1.75-3.40) were associated with malnutrition risk compared to well-nourished patients (p < 0.05). Median survival in patients with malnutrition risk was 21.3 months (range 14.1-28.4 95% CI) and median survival in patients who were defined as well nourished was not reached (p < 0.001). CONCLUSION The risk of malnutrition was associated with a higher risk for all-cause mortality in older patients with cancer, and was associated with many geriatric syndromes, including polypharmacy, fall risk, frailty, insomnia, and depression.
Collapse
Affiliation(s)
| | - Mehmet Besiroglu
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| | - Ayse Irem Yasin
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| | - Melih Simsek
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| | - Atakan Topcu
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| | - Lee Smith
- Centre for Health, Performance, and Wellbeing, Anglia Ruskin University, Cambridge, UK
| | - Baran Akagunduz
- Department of Medical Oncology, Erzincan Binali Yildirim University Medical School, Erzincan, Turkey
| | - Haci Mehmet Turk
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| | - Pinar Soysal
- Department of Geriatric Medicine, Bezmialem Vakif University, Istanbul, Turkey.
| |
Collapse
|
5
|
Topcu A, Yurtsever I, Isleyen ZS, Besiroglu M, Yasin AI, Topcu ZA, Shbair AT, Toluk O, Simsek M, Seker M, Turk HM. The correlation between skeletal muscle index and anxiety in patients with lung cancer on the first day of chemotherapy. Future Oncol 2023. [PMID: 37367530 DOI: 10.2217/fon-2022-1200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/28/2023] Open
Abstract
Aim: To evaluate the relationship between anxiety and skeletal muscle index (SMI) levels in lung cancer patients on the first day of chemotherapy. Materials & methods: This cross-sectional study included 108 patients. We analyzed patient characteristics, SMI levels, pain status and predicted anxiety factors. Results: Anxiety was detected in 61% of patients. SMI levels were significantly lower in the high anxiety group than the low anxiety group (p < 0.001). A significant correlation was observed between anxiety and SMI levels (r = -0.292; p = 0.002). Anxiety levels were significantly correlated with trait anxiety (r = 0.618; p < 0.001) and visual analog scale-pain (r = 0.364; p < 0.001). SMI (odds ratio: 0.94), trait anxiety (odds ratio: 1.12) and visual analog scale pain (odds ratio: 1.28) were independent risk factors for anxiety after adjusting for sex, stage and Eastern Cooperative Oncology Group performance status. Conclusion: Our study highlighted that higher anxiety scores were significantly correlated with lower SMI levels. We found that SMI, pain and trait anxiety were independent risk factors for anxiety.
Collapse
Affiliation(s)
- Atakan Topcu
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, 34093, Turkey
| | - Ismail Yurtsever
- Department of Radiology, Bezmialem Vakif University, Istanbul, 34093, Turkey
| | | | - Mehmet Besiroglu
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, 34093, Turkey
| | - Ayse Irem Yasin
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, 34093, Turkey
| | - Zeynep Alaca Topcu
- Department of Medical Oncology, Istanbul Medeniyet University, Istanbul, 34722, Turkey
| | - Abdallah Tm Shbair
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, 34093, Turkey
| | - Ozlem Toluk
- Department of Biostatistics, Bezmialem Vakif University, Istanbul, 34093, Turkey
| | - Melih Simsek
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, 34093, Turkey
| | - Mesut Seker
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, 34093, Turkey
| | - Haci Mehmet Turk
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, 34093, Turkey
| |
Collapse
|
6
|
Topcu A, Ozturk A, Yurtsever I, Besiroglu M, Yasin AI, Turk HM, Seker M. The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma. Bosn J Basic Med Sci 2022; 22:982-991. [DOI: 10.17305/bjbms.2022.7147] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Accepted: 04/29/2022] [Indexed: 11/16/2022] Open
Abstract
Erlotinib, a tyrosine kinase inhibitor, has been shown to improve the survival of patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. Sarcopenia is a status with increasing importance in lung cancer, and it may predict a poor prognosis. We aimed to evaluate the impact of sarcopenia on erlotinib therapy and prognosis in patients with EGFR-mutated (exon 19 or 21 L858R) metastatic lung adenocarcinoma. Sarcopenia was defined as skeletal muscle index ≤39 cm2/m2 for women and ≤55 cm2/m2 for men. The patient characteristics, inflammation parameters, clinical and survival outcomes of the erlotinib therapy were examined according to sarcopenia status. We also analyzed the erlotinib treatment-related toxicity. Seventy-two patients were included in our retrospective study, and the mean age of the patients was 63.7 years. A total of 39 (54.2%) patients were diagnosed with sarcopenia. Patients with sarcopenia had a poor prognosis and had a shorter median progression-free survival (PFS) than patients without sarcopenia (10.5 months vs. 21.8 months, p=0.002). Sarcopenia (HR 2.08) and C-reactive protein > 6.5 mg/L (HR 2.57) were determined as independent poor prognostic factors for PFS of erlotinib therapy. Treatment-related toxicity occurred in 34.7% of patients treated with erlotinib, and sarcopenia did not significantly affect treatment-related toxicity. We also found that sarcopenia significantly affected the response to erlotinib. The expected survival outcomes may be low when erlotinib therapy is used in patients with sarcopenia and metastatic lung adenocarcinoma. This study showed that survival and clinical outcomes could be better predicted by detecting sarcopenia in patients with lung cancer using erlotinib.
Collapse
|
7
|
Simsek M, Yasin AI, Besiroglu M, Topcu A, Isleyen ZS, Seker M, Turk HM. The Efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac Vaccines in Patients with Cancer. J Med Virol 2022; 94:4138-4143. [PMID: 35513241 PMCID: PMC9348062 DOI: 10.1002/jmv.27835] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Revised: 05/01/2022] [Accepted: 05/02/2022] [Indexed: 01/08/2023]
Abstract
Although vaccination is efficacious and prevents infection in the general population, there is limited data about Coronavirus disease‐19 (Covid‐19) occurrence after vaccination in cancer patients. It was aimed to evaluate the efficacy of BNT162b2 (Pfizer–BioNTech) and CoronaVac vaccines against Covid‐19 in patients with cancer. In this single‐center, retrospective, cross‐sectional, and descriptive study, the data of cancer patients referred to the medical oncology clinic of a university hospital were analyzed. The sample of the study consisted of cancer patients who had Covid‐19 or were vaccinated against Covid‐19. A total number of 2578 patients were included in the study. Of the patients, 2000 have never been infected with severe acute respiratory syndrome coronavirus and 578 patients have had a positive reverse‐transcription polymerase chain reaction (RT‐PCR) for Covid‐19. It was found that 2094 patients (81.2%) were fully vaccinated, and 484 patients (18.8%) did not receive full‐dose vaccination. A statistically significant difference in Covid‐19 occurrence was found between the patients who had full‐dose vaccination or not (p = 0.000). In in‐group comparisons of full‐dose vaccinated patients, while no difference was observed between two doses of BNT162b2 (Pfizer–BioNTech) and three doses of CoronaVac (p = 0.432), a statistically significant difference was observed between all other groups (p < 0.005). When the data of 578 patients who experienced Covid‐19 was analyzed, a statistically significant difference was observed between the groups who were full‐dose vaccinated and those who were not (p = 0.000). It is recommended that this vulnerable patient group should be prioritized in vaccination programs, and full‐dose vaccination (at least two doses of vaccines) should be completed as soon as possible.
Collapse
Affiliation(s)
- Melih Simsek
- BezmialemVakif University, Faculty of Medicine, Departments of Medical Oncology, Fatih/Istanbul, Turkey
| | - Ayse Irem Yasin
- BezmialemVakif University, Faculty of Medicine, Departments of Medical Oncology, Fatih/Istanbul, Turkey
| | - Mehmet Besiroglu
- BezmialemVakif University, Faculty of Medicine, Departments of Medical Oncology, Fatih/Istanbul, Turkey
| | - Atakan Topcu
- BezmialemVakif University, Faculty of Medicine, Departments of Medical Oncology, Fatih/Istanbul, Turkey
| | - Zehra Sucuoglu Isleyen
- BezmialemVakif University, Faculty of Medicine, Departments of Medical Oncology, Fatih/Istanbul, Turkey
| | - Mesut Seker
- BezmialemVakif University, Faculty of Medicine, Departments of Medical Oncology, Fatih/Istanbul, Turkey
| | - H Mehmet Turk
- BezmialemVakif University, Faculty of Medicine, Departments of Medical Oncology, Fatih/Istanbul, Turkey
| |
Collapse
|
8
|
Yasin AI, Aydin SG, Sümbül B, Koral L, Şimşek M, Geredeli Ç, Öztürk A, Perkin P, Demirtaş D, Erdemoglu E, Hacıbekiroglu İ, Çakır E, Tanrıkulu E, Çoban E, Ozcelik M, Çelik S, Teker F, Aksoy A, Fırat ST, Tekin Ö, Kalkan Z, Türken O, Oven BB, Dane F, Bilici A, Isıkdogan A, Seker M, Türk HM, Gümüş M. Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study. Future Oncol 2022; 18:1235-1244. [PMID: 35081732 PMCID: PMC8793921 DOI: 10.2217/fon-2021-1248] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Accepted: 12/09/2021] [Indexed: 12/13/2022] Open
Abstract
Aim: To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 noncancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: NCT04771559 (ClinicalTrials.gov).
Collapse
Affiliation(s)
- Ayse Irem Yasin
- Bezmialem Vakif University, Department of Medical Oncology, Istanbul 34093, Turkey
| | - Sabin Göktas Aydin
- Medipol University, Department of Medical Oncology, Istanbul 34214, Turkey
| | - Bilge Sümbül
- Bezmialem Vakif University, Department of Microbiology, Istanbul 34093, Turkey
| | - Lokman Koral
- Canakkale 18 March University, Department of Medical Oncology, Canakkale 17020 ,Turkey
| | - Melih Şimşek
- Bezmialem Vakif University, Department of Medical Oncology, Istanbul 34093, Turkey
| | - Çağlayan Geredeli
- Okmeydani Training and Research Hospital, Department of Medical Oncology, Istanbul 34384, Turkey
| | - Akın Öztürk
- SureyyapasaChest Dıseases And Thoracıc Surgery Traınıng And Research Hospıtal, Department of Medical Oncology, Istanbul 34844, Turkey
| | - Perihan Perkin
- Yildirim Beyazit University Yenimahalle Training and Research Hospital, Department of Medical Oncology, Ankara 06330, Turkey
| | - Derya Demirtaş
- AnkaraCity Hospital, Department of Medical Oncology, Ankara06800, Turkey
| | - Engin Erdemoglu
- GöztepeMedeniyet University, Department of Medical Oncology, Istanbul 34000, Turkey
| | - İlhan Hacıbekiroglu
- Sakarya University Medicine Faculty, Departmentof Medical Oncology, Sakarya 54050, Turkey
| | - Emre Çakır
- Sakarya University Medicine Faculty, Departmentof Medical Oncology, Sakarya 54050, Turkey
| | - Eda Tanrıkulu
- Haydarpasa Training and Research Hospital, University of Health Sciences, Istanbul 34668, Turkey
| | - Ezgi Çoban
- Haydarpasa Training and Research Hospital, University of Health Sciences, Istanbul 34668, Turkey
| | - Melike Ozcelik
- Marmara University School of Medicine, Department of Medical Oncology, Istanbul 34722, Turkey
| | - Sinemis Çelik
- Istanbul Oncology Hospital, Department of Medical Oncology, Istanbul 34846, Turkey
| | - Fatih Teker
- Gaziantep University, Department of Medical Oncology, Gaziantep 27470, Turkey
| | - Asude Aksoy
- Fırat University Faculty of Medicine, Department of Medical Oncology, Elazıg 23119, Turkey
| | - Sedat T Fırat
- Erciyes University, Department of Medical Oncology, Kayseri 38039, Turkey
| | - Ömer Tekin
- InönüUniversity, Department of Medical Oncology, Malatya 44280, Turkey
| | - Ziya Kalkan
- DicleUniversity, Department of Medical Oncology, Diyarbakır 21200, Turkey
| | - Orhan Türken
- MaltepeUniversity, Department of Medical Oncology, Istanbul 34844, Turkey
| | - Bala B Oven
- Bahcesehir University School of Medicine, Department of Medical Oncology, Istanbul 34349, Turkey
| | - Faysal Dane
- Acıbadem University, Department of MedicalOncology, Istanbul 34758, Turkey
| | - Ahmet Bilici
- Medipol University, Department of Medical Oncology, Istanbul 34214, Turkey
| | | | - Mesut Seker
- Bezmialem Vakif University, Department of Medical Oncology, Istanbul 34093, Turkey
| | - Hacı M Türk
- Bezmialem Vakif University, Department of Medical Oncology, Istanbul 34093, Turkey
| | - Mahmut Gümüş
- GöztepeMedeniyet University, Department of Medical Oncology, Istanbul 34000, Turkey
| |
Collapse
|
9
|
Abstract
Besides being the most frequently diagnosed cancer in women, breast cancer is the main cause of cancer-related deaths in this group of patients. Breast cancer frequently metastasizes to bone, lung, brain, and liver. Renal metastasis from the breast is extremely rare. Here we aimed to report a case of breast cancer with metastasis to bone and left renal pelvis. A 58-year old woman with a mass lesion in the left renal pelvis that mimicked urothelial carcinoma was referred to our clinic. The left nephroureterectomy procedure was performed, and the pathology revealed that a renal pelvis metastasis secondary to breast cancer.
Collapse
Affiliation(s)
- Abdallah TM Shbair
- Bezmialem Vakif University, Faculty of Medicine, Department of Medical Oncology, Istanbul, 34093, Turkey
| | - Ayse Irem Yasin
- Bezmialem Vakif University, Faculty of Medicine, Department of Medical Oncology, Istanbul, 34093, Turkey
| | - Atakan Topçu
- Bezmialem Vakif University, Faculty of Medicine, Department of Medical Oncology, Istanbul, 34093, Turkey
| | - Ganime Coban
- Bezmialem Vakif University, Faculty of Medicine, Department of Pathology, Istanbul, 34093, Turkey
| | - Gokce Deniz Uzunoglu
- Bezmialem Vakif University, Faculty of Medicine, Department of Radiology, Istanbul, 34093, Turkey
| | - Melih Şimşek
- Bezmialem Vakif University, Faculty of Medicine, Department of Medical Oncology, Istanbul, 34093, Turkey
| |
Collapse
|
10
|
Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol 2021; 17:4157-4169. [PMID: 34323116 DOI: 10.2217/fon-2021-0398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/13/2023] Open
Abstract
Aim: To evaluate the efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Methods: We retrospectively included 138 patients who were given trastuzumab-based chemotherapy as first-line treatment and analyzed the relationship between clinical response rates and maintenance treatment status and survival outcomes. Results: In the whole group, the median progression-free survival and overall survival were 10.2 and 16 months, respectively. Clinical response was obtained in 79% of patients. The median overall survival was 16.9 months in follow-up group and 19.0 months in the maintenance group in patients with clinical response. Continuation of maintenance trastuzumab created a significant survival advantage (p = 0.021). Eastern Cooperative Oncology Group performance status 2 (hazard ratio [HR]: 2.02), grade 3 (HR: 1.78) and more than four metastatic lesions (HR: 1.67) were determined as risk factors for death. Conclusion: We recommend the continuation of maintenance trastuzumab in patients with clinical response, but those with identified risk factors may not benefit from treatment because life expectancy may be low.
Collapse
Affiliation(s)
- Atakan Topcu
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul 34093, Turkey
| | - Muhammed Mustafa Atci
- Department of Medical Oncology, University of Health Sciences, Prof. Dr Cemil Tascioglu City Hospital, Istanbul 34384, Turkey
| | - Saban Secmeler
- Department of Medical Oncology, University of Health Sciences, Prof. Dr Cemil Tascioglu City Hospital, Istanbul 34384, Turkey
| | - Mehmet Besiroglu
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul 34093, Turkey
| | - Murat Ayhan
- Department of Medical Oncology, University of Health Sciences, Kartal Dr. Lutfi Kirdar Training & Research Hospital, Istanbul 34865, Turkey
| | - Metin Ozkan
- Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri 38030, Turkey
| | - Oktay Bozkurt
- Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri 38030, Turkey
| | - Zuhat Urakci
- Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakir 21280, Turkey
| | - Seval Ay
- Department of Medical Oncology, Medeniyet University Faculty of Medicine, Istanbul 34722, Turkey
| | - Caglayan Geredeli
- Department of Medical Oncology, University of Health Sciences, Prof. Dr Cemil Tascioglu City Hospital, Istanbul 34384, Turkey
| | - Ayse Irem Yasin
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul 34093, Turkey
| | - Haci Mehmet Turk
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul 34093, Turkey
| |
Collapse
|
11
|
Abstract
Aim: To compare anticholinergic burden (ACB) in older patients with and without cancer and evaluate the effects of ACB on geriatric syndromes. Methods: A total of 291 patients from the geriatric clinic and 301 patients from the oncology clinic were evaluated. ACB <2 was categorized as low ACB and ACB ≥2 was categorized as high ACB. A comprehensive geriatric assessment was performed on patients from the geriatric clinic. Results: ACB scores were significantly higher in patients without cancer compared with those with cancer (p < 0.005). Number of falls and Geriatric Depression Scale 15 scores were higher and Mini-Nutritional Assessment and Barthel/Lawton activities of daily living scores were lower in geriatric patients with high ACB scores compared with those with low ACB scores (p < 0.005). Conclusion: It is crucial to understand the potential effects of ACB for rational drug use and optimum cancer management in older patients with cancer.
Collapse
Affiliation(s)
- Ayse Irem Yasin
- Department of Medical Oncology, Bezmialem Vakıf University, Istanbul 34093, Turkey
| | - Atakan Topcu
- Department of Medical Oncology, Bezmialem Vakıf University, Istanbul 34093, Turkey
| | - Meysere Nur Akuc
- Department of Internal Medicine, Bezmialem Vakıf University, Istanbul 34093, Turkey
| | - Hacı Mehmet Türk
- Department of Medical Oncology, Bezmialem Vakıf University, Istanbul 34093, Turkey
| | - Pinar Soysal
- Department of Geriatrics, Bezmialem Vakıf University, Istanbul 34093, Turkey
| |
Collapse
|
12
|
Besiroglu M, Demir T, Shbair ATM, Yasin AI, Topcu A, Turk HM. Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting? J Coll Physicians Surg Pak 2021; 31:932-936. [PMID: 34320710 DOI: 10.29271/jcpsp.2021.08.932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/30/2021] [Accepted: 07/14/2021] [Indexed: 11/11/2022]
Abstract
OBJECTIVE To evaluate the predictive significance of the duration of temozolomide (TMZ) in patients with glioblastoma multiforme (GBM) who were treated with bevacizumab (Beva) as second-line setting. STUDY DESIGN Descriptive study. PLACE AND DURATION OF STUDY Bezmialem Vakif University School of Medicine Hospital, Istanbul, Turkey, from January 2014 to September 2020. METHODOLOGY A total of 109 patients, 47 (43.1%) females and 62 (56.9%) males, were retrospectively included in the study. All patients received TMZ as first-line and Beva as second-line treatment. Kaplan-Meier method and Cox regression model were performed for survival and univariate/multivariate analyses, respectively. RESULTS Patients treated with first-line TMZ were divided into two groups according to the PFS. Group 1 is <9 months and group 2 is ≥9 months. Overall survival (OS) of group 1 and group 2 patients was evaluated after the initiation of second-line bevacizumab treatment. The OS in group 1 was 7.8 months (6.9-8.6, 95% CI), and group 2 was eight months (6.4-9.5, 95% CI), but it was statistically non-significant (p = 0.837). CONCLUSION Duration of first-line TMZ treatment was not a predictor for OS of the GBM patients, who were treated with Beva as second-line setting. Key Words: Bevacizumab, Duration of treatment, Glioblastoma multiforme, Predictive score, Temozolomide.
Collapse
Affiliation(s)
- Mehmet Besiroglu
- Department of Medical Oncology, Bezmialem Vakıf University, Istanbul, Turkey
| | - Tarik Demir
- Department of Medical Oncology, Haydarpasa Numune Health Application and Research Center, Istanbul, Turkey
| | - Abdallah T M Shbair
- Department of Medical Oncology, Bezmialem Vakıf University, Istanbul, Turkey
| | - Ayse Irem Yasin
- Department of Medical Oncology, Bezmialem Vakıf University, Istanbul, Turkey
| | - Atakan Topcu
- Department of Medical Oncology, Bezmialem Vakıf University, Istanbul, Turkey
| | - Haci Mehmet Turk
- Department of Medical Oncology, Bezmialem Vakıf University, Istanbul, Turkey
| |
Collapse
|
13
|
Yasin AI, Topcu A, Shbair AT, Isleyen ZS, Ozturk A, Besiroglu M, Türk HM. Anxiety levels of breast cancer patients in Turkey during the COVID-19 pandemic. Future Oncol 2021; 17:3373-3381. [PMID: 34291649 PMCID: PMC8297541 DOI: 10.2217/fon-2020-1265] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Aim: To assess the anxiety levels of breast cancer patients during the COVID-19 pandemic. Materials & methods: A total of 298 patients completed the State-Trait Anxiety Inventory (STAI-S and STAI-T) and the Visual Analogue Scale for Anxiety (VAS) and VAS for Anxiety in COVID-19 (VAS-CoV). Results: 144 patients were in the high anxiety category for STAI-S, and 202 patients were in the high anxiety category for STAI-T. STAI-T score was significantly high in the metastatic group (p = 0.017). VAS-CoV score in the hormonotherapy group was significantly higher than in the no-treatment group (p = 0.023). There was a positive correlation between VAS-CoV and VAS levels (r = 0.708, p < 0.001), VAS-CoV and STAI-S and STAI-T scores (r = 0.402, p < 0.001; r = 0.185, p = 0.001, respectively), and a negative correlation between education years and STAI-T scores (r = -0.172, p = 0.003). Conclusion: The COVID-19 pandemic is related to high anxiety levels in breast cancer patients. COVID-19 pandemic is related to rapidly rising anxiety levels worldwide. Because of the high mortality of COVID-19 in cancer patients, changing treatment routines and disruptions of the healthcare system, cancer patients are the most affected population in this situation. Anxiety among females and breast cancer patients tend to be high, although anxiety levels in cancer patients during the pandemic period varies according to the cancer type, treatment status and sociodemographic factors. This study assessed the effect of the COVID-19 pandemic on breast cancer patients' anxiety levels according to treatment status and stage of the disease. A total of 298 breast cancer patients completed the universally validated anxiety questionnaires. Results demonstrated high trait anxiety in breast cancer patients, particularly in the metastatic group. The current findings highlighted the importance of intensive assessment and close monitoring of breast cancer patients' psychological situations. It is crucial to provide psychological support to breast cancer patients to contribute to both treatment and follow-up processes during the pandemic.
Collapse
Affiliation(s)
- Ayse Irem Yasin
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, 34093, Turkey
| | - Atakan Topcu
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, 34093, Turkey
| | - Abdallah Tm Shbair
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, 34093, Turkey
| | | | - Ahmet Ozturk
- Department of Psychiatry, Bezmialem Vakif University, Istanbul, 34093, Turkey
| | - Mehmet Besiroglu
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, 34093, Turkey
| | - Hacı Mehmet Türk
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, 34093, Turkey
| |
Collapse
|
14
|
Peker AA, Toprak H, Yasin AI, Aydin M. Uncommon Testicular Germ Cell Tumor Thrombus in Azygos Vein Detected by FDG PET/CT. Clin Nucl Med 2021; 46:e347-e348. [PMID: 33782290 DOI: 10.1097/rlu.0000000000003588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
ABSTRACT A 40-year old man admitted to the nuclear medicine department to undergo PET/CT for restaging of known testicular germ cell tumor. The patient had a history of orchiectomy for left testis and left nephrectomy with retroperitoneal lymph node dissection. Histopathology revealed testicular germ cell tumor. During the follow-up period, there is a rapidly expanding mass in posterior mediastinum. PET reveals increased FDG activity in the azygos vein. Contrast-enhanced CT of the thorax showed distended azygos vein with heterogeneously enhancing thrombus and peripheral fat stranding. Findings are consistent with azygos vein tumor thrombosis related to testicular germ cell tumor.
Collapse
Affiliation(s)
| | | | | | - Mehmet Aydin
- Nuclear Medicine, Bezmialem Vakıf University Faculty of Medicine, Istanbul, Turkey
| |
Collapse
|
15
|
Topcu A, Yasin AI, Shbair AT, Besiroglu M, Simsek M, Sucuoglu Z, Yurtsever I, Gucin Z, Seker M, Turk HM. A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer. J Oncol Pharm Pract 2021; 28:242-246. [PMID: 34162247 DOI: 10.1177/10781552211027931] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
INTRODUCTION Breast cancer is the most frequently diagnosed cancer in women worldwide. Ribociclib is now frequently used in the treatment of metastatic hormone-positive and human epidermal growth factor receptor 2 (HER 2)-negative breast cancer. CASE REPORT A 54-year-old woman with breast cancer presented at a clinic in November 2017 with multiple lung and bone metastases. After receiving multiple lines of treatment due to disease progression, ribociclib and fulvestrant were initiated. Grade 4 toxicity was observed due to ribociclib during follow-up, and ribociclib was discontinued permanently.Management & Outcome: Given that liver transaminases and bilirubin elevation persisted despite discontinuation of the treatment, other reasons for liver toxicity were investigated. Abdominal MRI showed no liver metastases, although there was acute hepatitis. A liver biopsy was performed to determine the etiology. The pathology result was compatible with drug-induced acute fulminant toxic hepatitis. After liver biopsy, prednisolone treatment was initiated, after which the laboratory findings normalized. DISCUSSION Although there are reported cases showing improvement in liver enzymes after ribociclib discontinuation, in our case, no recovery from hepatotoxicity was noticed. The treatment was changed to another hormonal pathway therapy option, exemestane. To the best of our knowledge, this is the first case in the literature reporting this rare side effect of ribociclib, which is a liver biopsy-proven fulminant hepatitis.
Collapse
Affiliation(s)
- Atakan Topcu
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| | - Ayse Irem Yasin
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| | - Abdallah Tm Shbair
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| | - Mehmet Besiroglu
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| | - Melih Simsek
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| | - Zehra Sucuoglu
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| | - Ismail Yurtsever
- Department of Radiology, Bezmialem Vakif University, Istanbul, Turkey
| | - Zuhal Gucin
- Department of Pathology, Bezmialem Vakif University, Istanbul, Turkey
| | - Mesut Seker
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| | - Haci Mehmet Turk
- Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| |
Collapse
|
16
|
Besiroglu M, Shbair AT, Yasin AI, Topcu A, Turk HM, Demir T. Systemic Inflammatory Markers for Prediction of Bevacizumab Benefit in Glioblastoma Multiforme. J Coll Physicians Surg Pak 2021; 31:39-44. [PMID: 33546531 DOI: 10.29271/jcpsp.2021.01.39] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Accepted: 12/28/2020] [Indexed: 11/11/2022]
Abstract
OBJECTIVE To evaluate the predictive significance of systemic inflammation markers (SIMs) in patients with glioblastoma multiforme (GBM), who were treated with bevacizumab (Beva). STUDY DESIGN Descriptive study. PLACE AND DURATION OF STUDY The study was conducted at the Bezmialem Vakif University School of Medicine Hospital, Istanbul, Turkey, from January 2014 to September 2019. METHODOLOGY A total of 107 patients, 49 (45.8%) female and 58 (54.2%) male, were retrospectively included in the study. The cut-off values for the SIMs-C-reactive protein to albumin ratio (CAR), neutrophil to lymphocyte (NLR) platelet to lymphocyte ratio (PLR), and systemic immune-inflammatory index (SIII))-were defined by receiver operating characteristic (ROC) analysis. Overall survival (OS) was plotted using the Kaplan-Meier method and compared using the log-rank test. Cox regression analysis was performed for univariate and multivariate analyses. RESULTS ROC analysis was performed to determine the optimal prognostic value of each parameter. CAR: 1.32, NLR: 2.9, PLR: 159, and SIII: 785 were determined as cut-off values for predicting OS based on the areas under the curve (AUC) in the ROC analysis. CAR at 0.626, had sensitivity of 67%, and specificity of 71% (p=0.129); NLR at 0.725 had sensitivity of 67%, and specificity of 79% (p=0.007); PLR at 0.675 had sensitivity of 67%, and specificity of 64% (p=0.036); and SIII at 0.685, had sensitivity of 56%, and specificity of 71% (p=0.026). A multivariate analysis demonstrated that CAR (p=0.006) and PLR (p=0.024) were independent prognostic factors for OS in patients with GBM, treated by Beva. CONCLUSION The present study's findings suggest that pretreatment CAR and PLR might be an independent predictive marker for patients with GBM, who are treated by Beva. Key Words: C-reactive protein-to-albumin ratio (AR), Glioblastoma multiforme, Neutrophil-to-lymphocyteratio (NLR), Platelet-to-lymphocyte ratio (PLR), Predictive score.
Collapse
Affiliation(s)
- Mehmet Besiroglu
- Department of Medical Oncology, Bezmialem Vakif University, School of Medicine Hospital, Istanbul, Turkey
| | - Abdallah Tm Shbair
- Department of Medical Oncology, Bezmialem Vakif University, School of Medicine Hospital, Istanbul, Turkey
| | - Ayse Irem Yasin
- Department of Medical Oncology, Bezmialem Vakif University, School of Medicine Hospital, Istanbul, Turkey
| | - Atakan Topcu
- Department of Medical Oncology, Bezmialem Vakif University, School of Medicine Hospital, Istanbul, Turkey
| | - Haci Mehmet Turk
- Department of Medical Oncology, Bezmialem Vakif University, School of Medicine Hospital, Istanbul, Turkey
| | - Tarik Demir
- Department of Medical Oncology, Haydarpaşa Numune Health Application and Research Center, Istanbul, Turkey
| |
Collapse
|